Document is current
Any future updates will be listed below
-
Authors
Liu, Dong https://orcid.org/0000-0001-8941-0812
Webber, Hannah C.
Bian, Fuyun
Xu, Yangfan
Prakash, Manjari
Feng, Xue
Yang, Ming
Yang, Hang
You, In-Jee https://orcid.org/0000-0002-6557-5337
Li, Liang https://orcid.org/0000-0002-6292-5995
Liu, Liping
Liu, Pingting https://orcid.org/0000-0003-1601-2818
Huang, Haoliang
Chang, Chien-Yi
Liu, Liang
Shah, Sahil H.
La Torre, Anna
Welsbie, Derek S.
Sun, Yang https://orcid.org/0000-0001-8735-4765
Duan, Xin https://orcid.org/0000-0001-5260-8972
Goldberg, Jeffrey Louis https://orcid.org/0000-0002-1390-7360
Braun, Marcus https://orcid.org/0000-0003-2026-2238
Lansky, Zdenek https://orcid.org/0000-0001-8474-053X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (EY024932, EY034353, 1F32EY029567, EY026877, EY032518, EY023295)
- License Information
-
More Information
Article History
Received: 10 April 2024
Accepted: 7 February 2025
First Online: 20 February 2025
Competing interests
: A PCT patent application entitled ‘Neuroprotection and Axon Regeneration Therapies for CNS Axonopathies By Modulating Mitochondria Trafficking through OPTN, TRAK1, and KIF5B’ has been filed by Stanford Office of Technology Licensing for international filing (International Application No. PCT/US2024/040324) for the AAV-mediated OPTN, TRAK1, and KIF5B overexpression identified in this manuscript. Yang Hu, Dong Liu, Haoliang Huang and Pingting Liu are coinventors, and Stanford University as the applicant of this patent. The other authors declare no competing interests.
